You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 4
  • OP007/#276 Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer

Article metrics

Article menu

Download PDFPDF

Oral Featured Posters
OP007/#276 Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to April 2024

AbstractFullPdf
Nov 202157021
Dec 202156010
Jan 20226508
Feb 20223403
Mar 20223103
Apr 20224107
May 202247018
Jun 202233012
Jul 20228209
Aug 20224808
Sep 20227005
Oct 202259014
Nov 20224003
Dec 20221603
Jan 20231703
Feb 20232003
Mar 202331010
Apr 20231705
May 20234504
Jun 20234602
Jul 20232405
Aug 20232401
Sep 20232003
Oct 20237208
Nov 2023190031
Dec 202316309
Jan 20243200
Feb 20242002
Mar 20243208
Apr 20241701
Total14490219